Yigit Ozpeynirci1, Cristian Capatana2, Johannes Rosskopf3, Bernd L Schmitz2,4, Gerhard F Hamann5, Michael Braun2. 1. Department of Neuroradiology, Ludwig Maximilian University, Munich, Germany. 2. Department of Neuroradiology, Bezirkskrankenhaus Gunzburg, Gunzburg, Germany. 3. Department of Radiology, Ulm University, Ulm, Germany. 4. Department of Neuroradiology, Ulm University, Ulm, Germany. 5. Clinic for Neurology and Neurologic Rehabilitation, Bezirkskrankenhaus Gunzburg, Gunzburg, Germany.
Abstract
BACKGROUND: Casper-RX (MicroVention, Aliso Viejo, California, USA) is a dual-layer closed cell stent recently introduced as a carotid artery revascularization device. Although its effectiveness and safety has been proved in elective cases, there are contradictive results regarding its patency in emergency settings. The purpose of the study is to present our single-center experience with the Casper-RX stent in the emergency interventions. PATIENTS AND METHODS: Consecutive patients who underwent emergency carotid artery stenting using Casper-RX system with or without additional intracranial thrombectomy between August 2016 and June 2019 at our institution were included. Primary end point was the short-term patency of the carotid stents evaluated before hospital discharge by use of Doppler ultrasonography. RESULTS: Twenty-nine procedures performed on 28 patients were included in the study. All stents were patent on final angiograms. Acute stent occlusion was observed only in one case (3.4%) with a spontaneous cervical internal carotid artery dissection the day after the procedure. In 26 (89.6%) cases, an additional intracranial thrombectomy was performed with a successful recanalization rate of 96.1%. Seven adverse events occurred peri-/post-procedural: two cases (6.9%) with iatrogenic dissection of distal cervical internal carotid artery during intracranial thrombectomy, two parenchymal hematoma type 2 (6.8%), and three patients (10.3%) developed massive infarction. CONCLUSION: This study supports the safety and efficacy of the Casper-RX stent in emergency endovascular carotid artery revascularization procedures.
BACKGROUND: Casper-RX (MicroVention, Aliso Viejo, California, USA) is a dual-layer closed cell stent recently introduced as a carotid artery revascularization device. Although its effectiveness and safety has been proved in elective cases, there are contradictive results regarding its patency in emergency settings. The purpose of the study is to present our single-center experience with the Casper-RX stent in the emergency interventions. PATIENTS AND METHODS: Consecutive patients who underwent emergency carotid artery stenting using Casper-RX system with or without additional intracranial thrombectomy between August 2016 and June 2019 at our institution were included. Primary end point was the short-term patency of the carotid stents evaluated before hospital discharge by use of Doppler ultrasonography. RESULTS: Twenty-nine procedures performed on 28 patients were included in the study. All stents were patent on final angiograms. Acute stent occlusion was observed only in one case (3.4%) with a spontaneous cervical internal carotid artery dissection the day after the procedure. In 26 (89.6%) cases, an additional intracranial thrombectomy was performed with a successful recanalization rate of 96.1%. Seven adverse events occurred peri-/post-procedural: two cases (6.9%) with iatrogenic dissection of distal cervical internal carotid artery during intracranial thrombectomy, two parenchymal hematoma type 2 (6.8%), and three patients (10.3%) developed massive infarction. CONCLUSION: This study supports the safety and efficacy of the Casper-RX stent in emergency endovascular carotid artery revascularization procedures.
Authors: Mayank Goyal; Bijoy K Menon; Wim H van Zwam; Diederik W J Dippel; Peter J Mitchell; Andrew M Demchuk; Antoni Dávalos; Charles B L M Majoie; Aad van der Lugt; Maria A de Miquel; Geoffrey A Donnan; Yvo B W E M Roos; Alain Bonafe; Reza Jahan; Hans-Christoph Diener; Lucie A van den Berg; Elad I Levy; Olvert A Berkhemer; Vitor M Pereira; Jeremy Rempel; Mònica Millán; Stephen M Davis; Daniel Roy; John Thornton; Luis San Román; Marc Ribó; Debbie Beumer; Bruce Stouch; Scott Brown; Bruce C V Campbell; Robert J van Oostenbrugge; Jeffrey L Saver; Michael D Hill; Tudor G Jovin Journal: Lancet Date: 2016-02-18 Impact factor: 79.321
Authors: Fritz Wodarg; Markus A Möhlenbruch; Johannes A R Pfaff; Christoph Maurer; Erasmia Broussalis; Hendrik Janssen; Raphael Blanc; Cyril Dargazanli; Vincent Costalat; Michel Piotin; Frank Runck; Ansgar Berlis; Monika Killer-Oberpfalzer; Johannes Tobias Hensler; Martin Bendszus Journal: J Neurointerv Surg Date: 2019-07-15 Impact factor: 5.836
Authors: Orlando Diaz; Gloria Lopez; John O F Roehm; Ginna De la Rosa; Fernando Orozco; Rafael Almeida Journal: J Neurointerv Surg Date: 2017-04-24 Impact factor: 5.836
Authors: H J Barnett; D W Taylor; M Eliasziw; A J Fox; G G Ferguson; R B Haynes; R N Rankin; G P Clagett; V C Hachinski; D L Sackett; K E Thorpe; H E Meldrum; J D Spence Journal: N Engl J Med Date: 1998-11-12 Impact factor: 91.245
Authors: Rüdiger von Kummer; Joseph P Broderick; Bruce C V Campbell; Andrew Demchuk; Mayank Goyal; Michael D Hill; Kilian M Treurniet; Charles B L M Majoie; Henk A Marquering; Michael V Mazya; Luis San Román; Jeffrey L Saver; Daniel Strbian; William Whiteley; Werner Hacke Journal: Stroke Date: 2015-09-01 Impact factor: 7.914